Discovery of Cell-Surface Vimentin (CSV) as a Sarcoma Target and Development of CSV-Targeted IL12 Immune Therapy

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Vimentin, typically intracellular, is found on the surface of aggressive tumor cells, including osteosarcoma (OS).
• Cell-surface vimentin (CSV) presents a potential target for capturing circulating tumor cells (CTCs), the source of metastasis.
• Interleukin-12 (IL12) is a cytokine with anti-tumor potential but often exhibits significant toxicity.

Purpose of the Study:

• To investigate cell-surface vimentin (CSV) as a target for osteosarcoma (OS) metastasis.
• To develop a novel CSV-targeted IL12 immunotherapy for OS.
• To evaluate the efficacy and safety of CSV-targeted IL12 in an OS mouse model.

Main Methods:

• Identification of CSV on aggressive OS cells and circulating tumor cells (CTCs).
• Engineering of a CSV-targeted IL12 by fusing a CSV-binding peptide (VNTANST) to the IL12 p40 subunit.
• Systemic administration of CSV-targeted IL12 in a mouse model of OS metastasis.

Main Results:

• The CSV-targeted IL12 effectively inhibited OS metastasis and prevented tumor relapse in the mouse model.
• Targeting CSV with IL12 demonstrated reduced systemic toxicity compared to conventional IL12.
• The VNTANST peptide successfully bound to CSV when conjugated to IL12.

Conclusions:

• Cell-surface vimentin (CSV) is a viable target for therapeutic strategies against osteosarcoma (OS) metastasis.
• CSV-targeted IL12 represents a promising, safer immunotherapy for managing OS metastasis.
• This approach offers a novel method for delivering IL12 therapy by targeting CSV on circulating tumor cells (CTCs).